J&J receives subpoenasUS attorneys in Boston, Philadelphia and San Francisco have issued subpoenas to Johnson & Johnson for marketing materials involving three of its subsidiaries—Ortho-McNeil for Topamax, Janssen for Risperdal and Scios for Natrecor.
J&J said the subpoenas seek information on its corporate supervision and oversight of the subsidiaries. A J&J statement said the company will cooperate.
Janssen, which increased Risperdal sales by 18% to $4.18 billion last year, received a subpoena in 2005 seeking information about the drug’s marketing and adverse reactions. Less than two years earlier, it received a subpoena from the Office of Personnel Management’s inspector-general seeking similar documents.
J&J’s Ortho-McNeil subsidiary, which increased Topamax sales by 21% to $2.03 billion last year, received a subpoena from the US Attorney’s Office in 2003 seeking documents relating to the drug’s marketing, including alleged “off-label” marketing, and a second subpoena last June.
In 2005, Scios received a subpoena from the US Attorney’s Office seeking documents regarding the sales and marketing of Natrecor, and Scios is responding to the subpoena, J&J said in the SEC filing.